Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

121.33 -0.60 (-0.49%)

Streaming Delayed Price Updated: 11:43 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Healthcare Sector Falters: S&P 500's Biggest Loser Amid Broader Market Caution

December 09, 2025

New York, NY – December 9, 2025 – The S&P 500 Healthcare sector found itself in a precarious position today, emerging as the biggest underperformer among its peers. While the broader S&P 500 index...

Via MarketMinute

Eaton, FTAI Aviation And More On CNBC's 'Final Trades' ↗

November 28, 2025

FTAI Aviation (NASDAQ: FTAI) is recommended by investment experts to diversify portfolios beyond tech, while Eaton (NYSE: ETN) and SPDR S&P Biotech ETF (NYSE: XBI) show promising price action. SoFi's...

Via Benzinga

Topics ETFs Stocks

Biotech Insiders Are Spending Billions. Trump Favors Less Oversight. One Biotech ETF Could Ride the Surge. ↗

November 17, 2025

The SPDR S&P Biotech ETF is a compelling investment option.

Via The Motley Fool

Topics ETFs Economy Government

Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral ↗

October 09, 2025

Via Stocktwits

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report ↗

September 26, 2025

Via Stocktwits

Money Moving Into Healthcare Not AI; Four Fed Presidents Do Not Want a Rate Cut; Euphoria Wearing Off ↗

November 13, 2025

Rotating To Healthcare Please click here for an enlarged chart comparing Invesco QQQ Trust Series 1 (NASDAQ:

Via Benzinga

Topics Economy

Taiwan Semiconductor, HealthEquity, Cboe Global Markets And More: CNBC's 'Final Trades' ↗

November 13, 2025

Stephen Weiss of Short Hills Capital Partners, named Taiwan Semiconductor Manufacturing Company as his final trade.

Via Benzinga

Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? ↗

November 03, 2025

Illumina's 23% post-earnings rally revives optimism across biotech ETFs as investors bet on a genomics rebound and ex-China growth in 2025.

Via Benzinga

Topics ETFs

FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ ↗

November 02, 2025

Things got murkier at the FDA’s drug evaluation agency as its acting director stepped down, alleging that a new drug approval program injected politics, superseding decisions based on science.

Via Stocktwits

Topics Lawsuit

Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin ↗

October 30, 2025

As markets enter their strongest stretch, ETFs tied to AI, banking, and healthcare could shine. Here's where investors are finding fresh momentum.

Via Benzinga

Topics Artificial Intelligence ETFs

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗

October 27, 2025

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.

Via Benzinga

Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today ↗

October 27, 2025

Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.

Via Stocktwits

Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts

October 19, 2025

The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗

October 15, 2025

SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures.

Via Benzinga

4 Biotech Stocks Seeing Explosive Momentum Gains ↗

October 07, 2025

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be...

Via Benzinga

Topics ETFs Stocks

How Trump's Shutdown Standoff Could Hand Health-Care ETFs A Lifeline ↗

October 07, 2025

Trump's comments on health-care negotiations with Democrats can put ETFs like XLV, IHF, and XHS back on investors' radar as Washington's shutdown drags on.

Via Benzinga

Topics ETFs Government

SciSparc And AutoMax Call Off Merger ↗

October 06, 2025

SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.

Via Benzinga

Eli Lilly Stock Jumps As Trump’s Drug Price Crackdown Spurs Sector Rally; Analysts Say Pfizer Deal Sets Template For Big Pharma ↗

September 30, 2025

Via Stocktwits

Topics Government

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Topics ETFs Government World Trade

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

September 25, 2025

Via Stocktwits

Topics Government

uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial ↗

September 24, 2025

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale.

Via Stocktwits

CrowdStrike, SoFi, Clearway Energy And More: CNBC's 'Final Trades' ↗

September 19, 2025

Experts on CNBC's Halftime Report discussed top trades for the day. SoFi hit an all-time high, Clearway Energy has strong dividend yield, CrowdStrike rose sharply, and SPDR S&P Biotech ETF gained...

Via Benzinga

Topics ETFs Stocks

As the Fed Pivots, These 3 ETFs Are Positioned to Outperform ↗

September 11, 2025

With the Fed pivoting from inflation fighter to growth supporter, these three ETFs offer the best leverage to falling rates.

Via The Motley Fool

Topics ETFs Economy

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗

September 09, 2025

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential...

Via Benzinga

Topics ETFs Government

Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy. ↗

August 22, 2025

The tariffs will impact products imported from Europe, the Trump administration said late Thursday.

Via Investor's Business Daily

Topics ETFs Government Intellectual Property

Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn ↗

July 16, 2025

President Donald Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month.

Via Investor's Business Daily

Topics ETFs Government World Trade

Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs ↗

July 08, 2025

President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."

Via Investor's Business Daily

Topics ETFs Economy Government

Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages ↗

June 29, 2025

ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according...

Via Stocktwits

Topics ETFs Intellectual Property

Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning ↗

June 24, 2025

The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review.

Via Stocktwits

Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data ↗

June 20, 2025

Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.